Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
Leuk Lymphoma
; 62(4): 828-836, 2021 04.
Article
in En
| MEDLINE
| ID: mdl-33274677
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Lymphoma, Large B-Cell, Diffuse
/
Receptors, Chimeric Antigen
Type of study:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Year:
2021
Type:
Article